Pieris Pharmaceuticals Investor Relations Material
Latest events
Business Combination
Pieris Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Pieris Pharmaceuticals Inc
Access all reports
Pieris Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on the discovery and development of Anticalin-based therapies, which are engineered proteins designed to treat respiratory diseases, cancer, and other conditions. The company’s proprietary Anticalin platform allows for the creation of novel biologics that target specific disease pathways. Pieris is developing a pipeline of therapies for immuno-oncology, asthma, and other respiratory conditions, working both independently and through collaborations with pharmaceutical partners. The company is headquartered in Boston, Massachusetts, and its shares are listed on the Nasdaq.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
PIRS
Country
🇺🇸 United States